Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Celtics Live

48

53

Halftime

Bruins Live

0

1

1st Prd 3:20

Novartis, Amgen join venture fund

The biopharmaceutical companies Novartis AG and Amgen Inc. have signed on as limited partners in a new $265 million venture capital fund raised by the Cambridge firm Atlas Venture.

The new fund, Atlas Venture Fund IX, will invest in biomedical and life sciences start-ups.

Continue reading below

Separately, Novartis, a Swiss company that runs its global research operations from Cambridge, and California-based Amgen, which also has a research center in ­Cambridge, have entered into corporate strategic partnerships with Atlas Venture, the partners said.

The alliances will “provide Amgen and Novartis with strategic proximity to Atlas Venture’s start-up formation activities around innovative, potentially high impact medicines, and catalyze future collaborations around translational research,” the venture firm said in a statement.

Robert Weisman can be reached at weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com